◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › SION

Sionna Therapeutics, Inc. (SION) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-10

Sionna Therapeutics, Inc. (SION) operates in the Biotechnology industry and is headquartered in Waltham, United States with about 59 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, SION reported $0M in revenue and ($75M) in net income.

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).

Interactive charts & full statements →

SION Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($89M)($71M)($50M)($41M)
Net Income($75M)($62M)($47M)($40M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SION Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($30M)($24M)($24M)($22M)($20M)
Net Income($27M)($20M)($20M)($18M)($16M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SION Free Cash Flow History

SION Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-31
Total Assets$326M$186M$52M$87M
Total Liabilities$19M$350M$167M$157M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SION viewer.

Other Companies in Biotechnology

← SINTAll stocksSIRI →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.